Medline stock
MDLNNASDAQMedline Inc., HealthcareISIN US58507V1070
55Score 55 out of 100, Neutral
Price and trend
64 / 100
Price history
−2.5% since 2025The chart shows daily closing prices since 17 Dec 2025, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.5% above it.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 20% below its 52-week high. Largest decline since 17 Dec 2025: 37% (February 2026 to September 2026).
Chart figures for advanced users
- SMA 50$35.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$39.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$31.64
- The lowest closing price of the last twelve months.
- Resistance$49.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Medline Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $35.13B, is number 5 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $28.43B (up 11.5% year on year) and earnings of $1.16B (down 3.4%).
- For fiscal 2026, analysts expect on average revenue of $31.33B (up 10.2%) and adjusted earnings per share of $1.53 (up 186.5%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 334 of 714 in Healthcare, median 53.
- Our model puts fair value at $43.35, with the price 3% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 421% of earnings over the last 12 months.Fundamentals 64
Weaknesses
- Interest barely coveredOperating profit covers interest only 2.5 times.Stability 60
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 60
Its standout strength is momentum, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $30.96 and expensive above $72.25 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $35.75, at 7.8% it would be $54.78.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 26 Sep 2026, revenue rose 10.4% on the same quarter a year earlier. Revenue has grown solidly since 2022, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 26%, operating 8%, net 4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.44 (expected $0.34)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.53+2.8%
- Revenue
- $31.33B+0.3%
- Earnings per share
- $1.55−0.8%
- Revenue
- $33.83B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −17.9%Organic sales guidance raised to 9% to 10% from 8.5% to 9.5%, but adjusted EBITDA guidance lowered to $3.3 billion to $3.4 billion from $3.5 billion to $3.6 billion.
“Given strong demand, continued commercial execution and broad-based momentum, we are raising our full year organic sales guidance for the second time this year to 9% to 10% from our previous range of 8.5% to 9.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $2.37B in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- GIC Private LtdSale
8 Oct 2026, Major holder
- Shares
- 7,816,987
- Price
- $35.15
- Value
- $274.77M
- GIC Private LtdSale
6 Oct 2026, Major holder
- Shares
- 9,272,000
- Price
- $35.05
- Value
- $324.98M
- GIC Private LtdSale
5 Oct 2026, Major holder
- Shares
- 1,688,690
- Price
- $35.78
- Value
- $60.42M
Show 7 more
- GIC Private LtdSale
2 Oct 2026, Major holder
- Shares
- 9,717,940
- Price
- $34.60
- Value
- $336.24M
- GIC Private LtdSale
14 Aug 2026, Major holder
- Shares
- 100,000
- Price
- $35.80
- Value
- $3.58M
- GIC Private LtdSale
13 Aug 2026, Major holder
- Shares
- 1,500,000
- Price
- $35.80
- Value
- $53.7M
- GIC Private LtdSale
7 Aug 2026, Major holder
- Shares
- 590,284
- Price
- $35.58
- Value
- $21M
- GIC Private LtdSale
6 Aug 2026, Major holder
- Shares
- 271,994
- Price
- $35.33
- Value
- $9.61M
- GIC Private LtdSale
5 Aug 2026, Major holder
- Shares
- 1,976,618
- Price
- $35.60
- Value
- $70.36M
- BCP 8 Holdings Mozart Manager L.L.C.Sale
28 May 2026, Major holder
- Shares
- 33,317,824
- Price
- $36.54
- Value
- $1.22B
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Medline
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Intuitive SurgicalISRG $155.83B76
- EssilorLuxotticaEL.PA $93.35B62
- Becton, DickinsonBDX $58.43B59
- HOYA7741.T $50.12B76
- ResMedRMD $33.55B84
- West Pharmaceutical ServicesWST $28.76B78
- Sartorius Stedim BiotechDIM.PA $24.55B58
- Straumann HoldingSTMN.SW $20.49B78
ETFs that hold Medline
Held by 61 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.83% | 0.25% | €44.3M |
| Amundi US Tech 100 Equal Weight UCITS ETF DR USDWEBA | 1.21% | 0.07% | €340.27M |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.44% | 0.20% | €268.74M |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.22% | 0.12% | €1.34B |
| iShares MSCI World Mid-Cap Equal Weight UCITS ETF USDIS3T | 0.17% | 0.30% | €408.01M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.17% | 0.30% | €51.58M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.16% | 0.25% | €4.18B |
| Invesco MSCI World Equal Weight UCITS ETF Acc AccumUSDMWEQ | 0.10% | 0.20% | €2.06B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.